Akoya BioSciences, Inc. - AKYA STOCK NEWS

Akoya Biosciences announced the appointment of Marilee Moy as Chief People Officer, effective January 20, 2022. With over 30 years of HR experience in the life sciences sector, Moy's leadership is expected to enhance Akoya's human resource strategy during its global growth phase. Her prior roles include senior positions at Talis Biomedical and Counsyl. Akoya focuses on spatial phenotyping, a groundbreaking approach in cell biology, potentially revolutionizing applications in medicine and research.

Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCycler™-Fusion system, revolutionizing spatial biology with its ability to map a million cells in just 10 minutes. This integrated platform combines high-speed imaging and ultrahigh multiplex cycling, allowing researchers to conduct large-scale biomarker discovery and validation efficiently. It can process over 300 samples weekly and incorporates RNA detection for comprehensive tissue analysis. The system enhances existing products, promising unbiased, rapid mapping of cellular interactions related to diseases.

Akoya Biosciences, Inc. (Nasdaq: AKYA) announced preliminary unaudited revenues for Q4 and full year 2021, with Q4 revenue expected between $16.0 million and $16.2 million, up from $12.9 million in Q4 2020. Full year revenue forecasts are between $54.8 million and $55.0 million, compared to $42.4 million in 2020. CEO Brian McKelligon highlighted significant progress, including a 30% revenue growth, an IPO, and near doubling of the company’s workforce. Despite these positive indicators, actual results remain subject to quarter-end adjustments.

Akoya Biosciences partners with Bio-Techne to develop the first single-cell, spatial multiomics workflow, enhancing the analysis of tissue samples. The PhenoCycler™-Fusion system, launching early January 2022, will automate protein and RNA imaging through RNAScope® technology. This collaboration aims to accelerate research in human health and complex diseases, offering new biomarker diagnostic signatures and improving treatment outcomes. Over 4,500 peer-reviewed publications back RNAScope assays, establishing them as a standard for spatial RNA imaging.

Bio-Techne (NASDAQ: TECH) and Akoya Biosciences (NASDAQ: AKYA) announced a partnership to develop a groundbreaking automated spatial multiomics workflow for tissue sample analysis. The collaboration aims to enhance RNA and protein analysis at single-cell resolution, facilitating better biomarker discovery and patient stratification in diseases like cancer. The partnership leverages Akoya's PhenoCycler-Fusion System and Bio-Techne's RNAScope HiPlex v2 assay, promising to accelerate research and improve treatment outcomes for complex diseases.

Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2022, at 9:00 a.m. ET. Brian McKelligon, CEO, will present the company's insights and developments. Investors can access both live and archived webcasts of this event through the Akoya website. As a leader in spatial biology, Akoya aims to enhance understanding of human health and disease through its innovative single-cell imaging solutions, including the CODEX® and Phenoptics™ platforms.

Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced a suite of innovations aimed at enhancing spatial biology research. Key highlights include the launch of the PhenoCycler-Fusion System, which enables mapping a million cells in under 10 minutes. The system combines ultrahigh multiplex cycling technology and high-speed imaging, allowing for faster and more detailed spatial discovery. Akoya will also introduce novel RNA and protein chemistries, facilitating comprehensive multiomic assessment. The commercial launch of the PhenoCycler-Fusion is set for January 2022, following limited distribution in December 2021.

Akoya Biosciences (Nasdaq: AKYA) and PathAI have partnered to enhance the discovery of predictive biomarkers for immunotherapies. This collaboration utilizes Akoya's Phenoptics™ spatial phenotyping platform and PathAI's AI algorithms to aid biopharmaceutical companies in identifying patients likely to respond to clinical trial treatments. The partnership aligns with Akoya's recent CLIA certification and aims to revolutionize cancer treatment through improved efficacy rates in immuno-oncology. Key insights into tumor microenvironments will accelerate drug development and clinical trials.

Akoya Biosciences (Nasdaq: AKYA) has achieved CLIA certification for its Advanced Biopharma Solutions laboratory in Marlborough, Massachusetts. This certification allows Akoya to support later-stage clinical trials and enhances its ability to develop and validate assays to meet high-quality standards. The certification positions Akoya as a valuable partner to biopharmaceutical companies, particularly in cancer immunotherapy. This advance follows prior milestones, including a publication demonstrating Akoya's spatial biology technology's effectiveness in clinical settings.